News Release

Biotech Support Group to exhibit at the 67th ASMS Conference on Mass Spectrometry & Allied Topics

MONMOUTH JUNCTION, NJ, May 2, 2019 -- Biotech Support Group will exhibit at the annual ASMS Conference, June 2-6, 2019 in Atlanta, GA. The American Society for Mass Spectrometry (ASMS) was formed in 1969 to promote and disseminate knowledge of mass spectrometry and allied topics. ASMS sponsors the Annual Conference on Mass Spectrometry and Allied Topics that is attended by more than 6,500 scientists from academic, industrial and governmental laboratories. Over 3,000 papers are presented as posters and talks.

Featured at our Booth 719, will be a patent pending cancer biomarker panel we plan to commercialize through partnerships, and consumable sample prep products for blood proteome enrichment. In addition, we will be presenting a technical poster report entitled “AlbuVoid™ Enrichment & Antibody Depletion - Solving the Challenges of Serum Proteomics”.

Abstract

Proteomic workflows that support serum proteomics can be especially challenging for two reasons: 1) the presence of highly abundant proteins, Albumin alone accounts for about 50% of the total protein mass, and 2) a particularly proteolytic resistant sample type due the large concentration of antibodies present. Many proteomic enrichment strategies employ the use of immuno-affinity depletion to remove one or more high abundance proteins. Some common limitations of immuno-affinity however are high costs, regeneration requirements which may result in a diminished and inconsistent performance, as well as a required marriage of species to antibody. Because of these limitations, researchers need ways to enrich differently.

Methods

The vast majority of the plasma proteome falls into functional categories; by mass content these are: Albumin 50-60%; Immunoglobulins 10-20%; Transport (Transferrin, Apo) 5-10%; Complement related Proteins 3-5%; Protease Inhibitors 2-5%; and all others 2-5%. While these categorical sub-proteomes are required for normal body homeostasis, they nevertheless become dysfunctional during acute-phase and chronic stimuli. As a result, categorically the acute-phase sub-proteomes differentiated in disease may vary greatly from those associated with chronic sub-proteomes. So there is great benefit in having options to enrich or deplete one or more of these sub-proteomes. Herein, we report the serum proteome bias characteristics, both qualitative and quantitative, of the products AlbuVoid™ & NuGel™ Protein A, alone or in serial combination (AlbuVoid™ PLUS), using LC-MS reporting metrics.

Results

With our new data, we have compiled a qualitative and quantitative knowledgebase of over 1000 serum proteins observable by our Albumin depletion products and methods. This knowledgebase will help LC-MS researchers decide which product/method combination may be best for discovery purposes. Likewise, if target proteins are known or suspected, the knowledgebase can guide the researcher towards the best available products/methods for quantitative targeted proteomic analysis. We give an example of how we have used that information in targeted proteomic profiling of cancer sera vs. normal sera differentiation.

"We will be highlighting our many successes over the past 6 months at this Conference. This includes our patent application on our cancer biomarker panel, called Stroma Liquid Biopsy™ now available for commercial partnerships. Also, we report on our most recent data on our consumable proteomic sample prep product, called AlbuVoid™ PLUS which couples immunoglobulin depletion, called NuGel™ Protein A with AlbuVoid™. It is very exciting to share these developments with a dedicated group at the forefront of mass spectrometry research”, states Dr. Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information on the BSG complete line of Albumin & IgG Removal products, visit: https://www.biotechsupportgroup.com/Articles.asp?ID=451

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, visit: https://www.biotechsupportgroup.com

Contact:
Matthew Kuruc 732-274-2866
mkuruc@biotechsupportgroup.com